Cargando…
Glucocorticoids Are Not Associated with Bone Mineral Density in Patients with Polymyalgia Rheumatica, Giant Cell Arteritis and Other Vasculitides—Cross-Sectional Baseline Analysis of the Prospective Rh-GIOP Cohort
Background: Glucocorticoids (GCs) can cause osteoporosis (OP). Prior observational research on bone density and the effects of GCs in polymyalgia rheumatica (PMR) and vasculitides is scarce and inconclusive. Methods: Rh-GIOP is a prospective cohort study of bone health in patients with inflammatory...
Autores principales: | Palmowski, Andriko, Wiebe, Edgar, Muche, Burkhard, Hermann, Sandra, Dejaco, Christian, Matteson, Eric L., Buttgereit, Frank |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834394/ https://www.ncbi.nlm.nih.gov/pubmed/35159345 http://dx.doi.org/10.3390/cells11030536 |
Ejemplares similares
-
No association between methotrexate and impaired bone mineral density in a cohort of patients with polymyalgia rheumatica, giant cell arteritis, granulomatosis with polyangiitis and other vasculitides—a cross-sectional analysis with dose–response analyses
por: Palmowski, Andriko, et al.
Publicado: (2023) -
Prognostic impacts of glucocorticoid treatment in patients with polymyalgia rheumatica and giant cell arteritis
por: Emamifar, Amir, et al.
Publicado: (2021) -
Is Tocilizumab Effective and Safe in Polymyalgia Rheumatica and Giant-Cell Arteritis With Polymyalgia Rheumatica?
por: Farinango, Michelle, et al.
Publicado: (2022) -
Genetic Predispositions of Glucocorticoid Resistance and Therapeutic Outcomes in Polymyalgia Rheumatica and Giant Cell Arteritis
por: Smutny, Tomas, et al.
Publicado: (2019) -
Optimal management of giant cell arteritis and polymyalgia rheumatica
por: Charlton, Rodger
Publicado: (2012)